맞춤형 의료 바이오마커 시장 규모, 점유율, 동향 분석 보고서 : 용도별, 적응증별, 지역별, 부문별 예측(2025-2030년)

Personalized Medicine Biomarkers Market Size, Share & Trends Analysis Report By Application (Early Detection, Treatment Selection, Monitoring), By Indication (Oncology, Neurology), By Region, And Segment Forecasts, 2025 - 2030

US $ 5,950 ￦ 8,828,000

Unprintable PDF & Excel (Single User License)

보고서 PDF 및 엑셀을 1인만 사용할 수 있는 라이선스입니다. 텍스트 등의 복사 및 붙여넣기, 인쇄는 불가능합니다.

US $ 6,950 ￦ 10,311,000

Printable PDF & Excel (5-User License)

보고서 PDF 및 엑셀을 동일 기업 내 동일 부서에서 최대 5명까지 사용할 수 있는 라이선스입니다. 텍스트 등의 복사 및 붙여넣기, 인쇄는 가능합니다.

US $ 8,950 ￦ 13,279,000

Printable PDF & Excel (Enterprise License)

PDF & Excel 보고서를 동일 기업(자회사 포함)의 모든 분이 이용할 수 있는 라이선스입니다. 텍스트 등의 복사 및 붙여넣기, 인쇄는 가능합니다. 인쇄물의 이용 범위는 파일의 이용 범위와 동일합니다.

한글목차

맞춤형 의료 바이오마커 시장 성장과 동향:

Grand View Research, Inc.의 최신 보고서에 따르면, 세계 맞춤형 의료 바이오마커 시장 규모는 2025년부터 2030년까지 13.6%의 CAGR을 기록하여 2030년까지 471억 6,000만 달러에 달할 것으로 예상됩니다. 도달할 것으로 추정됩니다.

이러한 성장은 인식의 증가, 예후 예측의 중요성, 복용량 선택에 대한 인식이 높아졌기 때문입니다. 또한, 맞춤형 의료 바이오마커는 환자를 선별하고 적절한 환자에게 적절한 치료를 제공하는 데 필수적인 도구로 작용하여 맞춤형 의료 바이오마커에 대한 수요를 더욱 촉진하고 있습니다.

바이오마커는 진단 예측 치료 결과 개선 및 치료 방침 결정에 활용할 수 있는 독특한 분석물입니다. 바이오마커는 맞춤형 의료에 필수적입니다. 환자의 예후를 개선하기 위한 바이오마커의 활용은 임상시험에서 활발히 진행되고 있으며, 임상에서의 활용은 빠르게 확대되고 있습니다. 바이오마커를 활용한 맞춤의료의 개발로 모든 환자에게 효과적이고 안전한 치료법을 만들 수 있을 것으로 기대됩니다. 이는 암과 같은 만성질환의 진행 단계에 있는 환자들에게 큰 안도감을 주며, 시장 성장을 더욱 촉진할 것입니다. 예를 들어, 2022년 8월 FDA는 펨브롤리주맙 치료를 받을 수 있는 진행성 암 환자를 식별하는 데 사용되는 최초의 IHC 기반 분석법인 VENTANA MMR RxDx Panel을 승인했습니다.

조기발견/스크리닝 바이오마커는 치료 전 환자군의 질병 결과를 예측할 수 있습니다. 또한, 치료에 반응하기 쉬운 환자를 선별하여 임상시험을 강화하는 데에도 도움이 됩니다. 예를 들어, Oncotype Dx는 Genomic Health가 개발한 진단 검사입니다. 이 검사는 21개의 유전자를 검사하여 1차 치료 후 환자의 유방암 재발 가능성을 예측하는 데 도움을 주며, 2022년 4월 ASCO의 가이드라인이 업데이트되어 조기 유방암 환자에게 Oncotype DX 검사 사용을 권장하여 치료 결정에 도움을 줄 수 있게 되었습니다.

또한, 바이오마커는 건강 상태의 발생을 예측하는 데 도움이 되는 예측 및 예후 유용성을 위해 사용됩니다. 예를 들어, 전립선 특이 항원은 전립선암 환자의 생존을 예측하는 데 사용되며, CRP는 유방암의 무병 생존율을 예측하고 심혈관질환의 위험 요인으로 사용됩니다. 혈청 LDH는 전이성 뇌종양의 생존 예측에 도움이 됩니다. 마찬가지로 CA125는 자궁암 환자의 전이성 질환을 예측하는 데 도움이 됩니다.

또한, 맞춤형 의료 바이오마커 산업에서 활동하는 주요 기업들은 다양한 용도로 사용할 수 있는 제품을 확장하고 출시하는 데 주력하고 있습니다. 예를 들어, 2021년 10월 애질런트 테크놀러지스(Agilent Technologies Inc.)는 유방암 재발 위험이 높은 환자를 식별하기 위한 애질런트 Ki-67 IHC MIB-1 pharmDx(Dako Omnis)의 FDA 승인을 획득했습니다.

맞춤형 의료 바이오마커 시장 보고서 하이라이트

• 용도별로는 조기 발견/스크리닝 분야가 환자의 조기 치료 필요성으로 인해 가장 빠른 CAGR로 성장할 것으로 예상됩니다.
• 적응증별로는 암 유병률의 증가와 FDA 승인 암 개인화 바이오마커 검사가 널리 보급됨에 따라 2024년 암 분야가 가장 큰 시장 점유율을 차지했습니다.
• 북미는 의료 인프라 개선, 대상 질환의 유병률 증가, 바이오마커 혁신에 대한 정부 자금 지원 증가로 인해 가장 큰 시장 점유율을 차지했습니다.

목차

제1장 조사 방법과 범위

제2장 주요 요약

제3장 맞춤형 의료 바이오마커 시장 변수, 동향, 범위

• 시장 계통 전망
  • 상부 시장 전망
  • 관련/부수 시장 전망
• 시장 역학
  • 시장 성장 촉진요인 분석
  • 시장 성장 억제요인 분석
• 맞춤형 의료 바이오마커 시장 분석 툴
  • 업계 분석 - Porter's Five Forces 분석
  • PESTEL 분석

제4장 맞춤형 의료 바이오마커 시장 : 용도 추정·동향 분석

• 부문 대시보드
• 맞춤형 의료 바이오마커 시장 : 적응증 변동 분석
• 맞춤형 의료 바이오마커 시장 전망 : 적응증별
• 시장 규모와 예측과 동향 분석, 2018-2030년
• 조기 발견·스크리닝
• 진단
• 치료 선택
• 모니터링

제5장 맞춤형 의료 바이오마커 시장 : 적응증 추정·동향 분석

• 부문 대시보드
• 맞춤형 의료 바이오마커 시장 : 바이오마커 변동 분석
• 맞춤형 의료 바이오마커 시장 : 바이오마커별 전망
• 시장 규모와 예측과 동향 분석, 2018-2030년
• 종양학
• 신경학
• 당뇨병
• 자가면역질환
• 심장병학
• 기타

제6장 맞춤형 의료 바이오마커 시장 : 지역 추정·동향 분석

• 지역 대시보드
• 시장 규모, 예측 동향 분석, 2018-2030년 :
• 북미
  • 미국
  • 캐나다
  • 멕시코
• 유럽
  • 영국
  • 독일
  • 프랑스
  • 이탈리아
  • 스페인
  • 노르웨이
  • 스웨덴
  • 덴마크
• 아시아태평양
  • 일본
  • 중국
  • 인도
  • 호주
  • 한국
  • 태국
• 라틴아메리카
  • 브라질
  • 아르헨티나
• 중동 및 아프리카
  • 남아프리카공화국
  • 사우디아라비아
  • 아랍에미리트
  • 쿠웨이트

제7장 경쟁 구도

• 기업 분류
• 최근 동향과 영향 분석, 주요 시장 진출 기업별
• 기업 시장 점유율 분석, 2024년
• 기업 개요
  • Laboratory Corporation of America Holding
  • Quest Diagnostics Incorporated
  • Agilent Technologies, Inc
  • Genome Medical, Inc
  • Thermo Fisher Scientific, Inc
  • Coriell Life Sciences
  • NeoGenomics Laboratories
  • FOUNDATION MEDICINE, INC
  • Illumina, Inc
  • Guardant Health

ksm

영문 목차

영문목차

Personalized Medicine Biomarkers Market Growth & Trends:

The global personalized medicine biomarkers market size is estimated to reach USD 47.16 billion by 2030, registering a CAGR of 13.6% from 2025 to 2030, according to a new report by Grand View Research, Inc. The growth is attributed to the rising awareness, importance of predicting prognosis, and selection of dose. Moreover, personalized medicine biomarkers serve as an essential tool for the selection of patients and providing the right treatment to the right patient further propelling the demand for personalized medicine biomarkers.

Biomarkers are unique analytes that can be utilized to improve diagnosis forecast treatment outcomes and direct treatment decisions. They are crucial to personalized medicine. The increased usage of biomarkers to enhance patient outcomes is popular in clinical trials, and its use in clinical practice is expanding quickly. The development of personalized medicines using biomarkers is expected to create effective and safe therapies for every patient. This is a major relief for patients at advanced stages of chronic diseases like cancer, which further drives the market growth. For instance, in August 2022, VENTANA MMR RxDx Panel, an FDA approved first IHC-based assay used for the identification of patients with advanced cancer that is Pembrolizumab treatment eligible.

Early detection/screening biomarkers predict the outcome of disease in patient population prior to therapy. It can also help enrich clinical trials by helping choose patients more likely to respond to treatment. For instance, Oncotype Dx is a diagnostic test developed by Genomic Health, Inc. This test examines 21 genes and helps predict the likelihood of reoccurrence of breast cancer in a patient after initial treatment. In April 2022, updated ASCO guidelines recommended the usage of the Oncotype DX test for breast cancer patients at early stages to guide treatment decisions.

Moreover, biomarkers are used for their predictive and prognostic utility that helps predict the occurrence of a health condition. For instance, the prostate-specific antigen is used to predict the survival of patients with prostate cancer. CRP is used to predict disease-free survival in breast cancer and as a risk factor in cardiovascular disorders. Serum LDH helps predict survival in case of metastatic brain tumors. Similarly, CA125 helps predict metastatic diseases in patients with uterine carcinoma.

Furthermore, key players operating in the personalized medicine biomarkers industry are focusing on expanding and launching products that can be used for a wide range of applications. For instance, in October 2021, Agilent Technologies Inc. received FDA approval for Agilent Ki-67 IHC MIB-1 pharmDx (Dako Omnis), for the identification of patients with a high risk of breast cancer recurrence.

Personalized Medicine Biomarkers Market Report Highlights:

• Based on application, the early detection/screening segment is expected to grow at the fastest CAGR owing to the need to provide early treatment to patients.
• By indication, the oncology segment held the largest market share in 2024, owing to the rising prevalence of cancer and the wide availability of FDA-approved personalized biomarkers tests for cancer
• North America held the largest market share attributable to the presence of improved healthcare infrastructure, rising prevalence of target diseases, and increasing government funding for innovation in biomarkers.

Table of Contents

Chapter 1. Methodology and Scope

• 1.1. Market Segmentation and Scope
• 1.2. Segment Definitions
  • 1.2.1. Indication
  • 1.2.2. Application
  • 1.2.3. Regional Scope
  • 1.2.4. Estimates and forecasts timeline
• 1.3. Research Methodology
• 1.4. Information Procurement
  • 1.4.1. Purchased database
  • 1.4.2. GVR's internal database
  • 1.4.3. Secondary sources
  • 1.4.4. Primary research
  • 1.4.5. Details of primary research
• 1.5. Information or Data Analysis
  • 1.5.1. Data analysis models
• 1.6. Market Formulation & Validation
• 1.7. Model Details
  • 1.7.1. Commodity flow analysis (Model 1)
  • 1.7.2. Approach 1: Commodity flow approach
  • 1.7.3. Volume price analysis (Model 2)
  • 1.7.4. Approach 2: Volume price analysis
• 1.8. List of Secondary Sources
• 1.9. List of Primary Sources
• 1.10. Objectives

Chapter 2. Executive Summary

• 2.1. Market Outlook
• 2.2. Segment Outlook
  • 2.2.1. Application outlook
  • 2.2.2. Indication outlook
• 2.3. Regional outlook
• 2.4. Competitive Insights

Chapter 3. Personalized Medicine Biomarkers Market Variables, Trends & Scope

• 3.1. Market Lineage Outlook
  • 3.1.1. Parent Market Outlook
  • 3.1.2. Related/ancillary market outlook
• 3.2. Market Dynamics
  • 3.2.1. Market Driver Analysis
    • 3.2.1.1. Increasing prevalence of chronic diseases
    • 3.2.1.2. Rising awareness and importance of predicting prognosis and selection of dose
    • 3.2.1.3. Need to provide early diagnosis and treatment
  • 3.2.2. Market Restraint Analysis
    • 3.2.2.1. Regulatory & reimbursement hurdles
• 3.3. Personalized Medicine Biomarkers Market Analysis Tools
  • 3.3.1. Industry Analysis - Porter's
    • 3.3.1.1. Bargaining power of suppliers
    • 3.3.1.2. Bargaining power of buyers
    • 3.3.1.3. Threat of substitutes
    • 3.3.1.4. Threat of new entrants
    • 3.3.1.5. Competitive rivalry
  • 3.3.2. PESTEL Analysis
    • 3.3.2.1. Political landscape
    • 3.3.2.2. Economic landscape
    • 3.3.2.3. Social landscape
    • 3.3.2.4. Technological landscape
    • 3.3.2.5. Environmental landscape
    • 3.3.2.6. Legal landscape

Chapter 4. Personalized Medicine Biomarkers Market: Application Estimates & Trend Analysis

• 4.1. Segment Dashboard
• 4.2. Personalized Medicine Biomarkers Market: Indication Movement Analysis
• 4.3. Personalized Medicine Biomarkers Market by Indication Outlook (USD Million)
• 4.4. Market Size & Forecasts and Trend Analyses, 2018 to 2030 for the following
• 4.5. Early Detection/Screening
  • 4.5.1. Market Estimates And Forecast, 2018 - 2030 (USD Million)
• 4.6. Diagnosis
  • 4.6.1. Market Estimates And Forecast, 2018 - 2030 (USD Million)
• 4.7. Treatment Selection
  • 4.7.1. Market Estimates And Forecast, 2018 - 2030 (USD Million)
• 4.8. Monitoring
  • 4.8.1. Market Estimates And Forecast, 2018 - 2030 (USD Million)

Chapter 5. Personalized Medicine Biomarkers Market: Indication Estimates & Trend Analysis

• 5.1. Segment Dashboard
• 5.2. Personalized Medicine Biomarkers Market: Biomarker Movement Analysis
• 5.3. Personalized Medicine Biomarkers Market by Biomarker Outlook (USD Million)
• 5.4. Market Size & Forecasts and Trend Analyses, 2018 to 2030 for the following
• 5.5. Oncology
  • 5.5.1. By Type Market Estimates And Forecast, 2018 - 2030 (USD Million)
    • 5.5.1.1. Breast Cancer
      • 5.5.1.1.1. Market Estimates And Forecast, 2018 - 2030 (USD Million)
    • 5.5.1.2. Lung Cancer
      • 5.5.1.2.1. Market Estimates And Forecast, 2018 - 2030 (USD Million)
    • 5.5.1.3. Colon Cancer
      • 5.5.1.3.1. Market Estimates And Forecast, 2018 - 2030 (USD Million)
    • 5.5.1.4. Others
      • 5.5.1.4.1. Market Estimates And Forecast, 2018 - 2030 (USD Million)
  • 5.5.2. By Circulating Biomarkers Market Estimates And Forecast, 2018 - 2030 (USD Million)
    • 5.5.2.1. Circulating Tumor Cells
      • 5.5.2.1.1. Market Estimates And Forecast, 2018 - 2030 (USD Million)
    • 5.5.2.2. Circulating Cell-free DNA
      • 5.5.2.2.1. Market Estimates And Forecast, 2018 - 2030 (USD Million)
    • 5.5.2.3. Extracellular Vesicles
      • 5.5.2.3.1. Market Estimates And Forecast, 2018 - 2030 (USD Million)
    • 5.5.2.4. Other Circulating Biomarkers
      • 5.5.2.4.1. Market Estimates And Forecast, 2018 - 2030 (USD Million)
• 5.6. Neurology
  • 5.6.1. Market Estimates And Forecast, 2018 - 2030 (USD Million)
• 5.7. Diabetes
  • 5.7.1. Market Estimates And Forecast, 2018 - 2030 (USD Million)
• 5.8. Autoimmune Diseases
  • 5.8.1. Market Estimates And Forecast, 2018 - 2030 (USD Million)
• 5.9. Cardiology
  • 5.9.1. Market Estimates And Forecast, 2018 - 2030 (USD Million)
• 5.10. Others
  • 5.10.1. Market Estimates And Forecast, 2018 - 2030 (USD Million)

Chapter 6. Personalized Medicine Biomarkers Market: Regional Estimates & Trend Analysis

• 6.1. Regional Dashboard
• 6.2. Market Size, & Forecasts Trend Analysis, 2018 to 2030:
• 6.3. North America
  • 6.3.1. U.S.
    • 6.3.1.1. Key country dynamics
    • 6.3.1.2. Regulatory framework/ reimbursement structure
    • 6.3.1.3. Competitive scenario
    • 6.3.1.4. U.S. market estimates and forecasts 2018 to 2030 (USD Million)
  • 6.3.2. Canada
    • 6.3.2.1. Key country dynamics
    • 6.3.2.2. Regulatory framework/ reimbursement structure
    • 6.3.2.3. Competitive scenario
    • 6.3.2.4. Canada market estimates and forecasts 2018 to 2030 (USD Million)
  • 6.3.3. Mexico
    • 6.3.3.1. Key country dynamics
    • 6.3.3.2. Regulatory framework/ reimbursement structure
    • 6.3.3.3. Competitive scenario
    • 6.3.3.4. Mexico market estimates and forecasts 2018 to 2030 (USD Million)
• 6.4. Europe
  • 6.4.1. UK
    • 6.4.1.1. Key country dynamics
    • 6.4.1.2. Regulatory framework/ reimbursement structure
    • 6.4.1.3. Competitive scenario
    • 6.4.1.4. UK market estimates and forecasts 2018 to 2030 (USD Million)
  • 6.4.2. Germany
    • 6.4.2.1. Key country dynamics
    • 6.4.2.2. Regulatory framework/ reimbursement structure
    • 6.4.2.3. Competitive scenario
    • 6.4.2.4. Germany market estimates and forecasts 2018 to 2030 (USD Million)
  • 6.4.3. France
    • 6.4.3.1. Key country dynamics
    • 6.4.3.2. Regulatory framework/ reimbursement structure
    • 6.4.3.3. Competitive scenario
    • 6.4.3.4. France market estimates and forecasts 2018 to 2030 (USD Million)
  • 6.4.4. Italy
    • 6.4.4.1. Key country dynamics
    • 6.4.4.2. Regulatory framework/ reimbursement structure
    • 6.4.4.3. Competitive scenario
    • 6.4.4.4. Italy market estimates and forecasts 2018 to 2030 (USD Million)
  • 6.4.5. Spain
    • 6.4.5.1. Key country dynamics
    • 6.4.5.2. Regulatory framework/ reimbursement structure
    • 6.4.5.3. Competitive scenario
    • 6.4.5.4. Spain market estimates and forecasts 2018 to 2030 (USD Million)
  • 6.4.6. Norway
    • 6.4.6.1. Key country dynamics
    • 6.4.6.2. Regulatory framework/ reimbursement structure
    • 6.4.6.3. Competitive scenario
    • 6.4.6.4. Norway market estimates and forecasts 2018 to 2030 (USD Million)
  • 6.4.7. Sweden
    • 6.4.7.1. Key country dynamics
    • 6.4.7.2. Regulatory framework/ reimbursement structure
    • 6.4.7.3. Competitive scenario
    • 6.4.7.4. Sweden market estimates and forecasts 2018 to 2030 (USD Million)
  • 6.4.8. Denmark
    • 6.4.8.1. Key country dynamics
    • 6.4.8.2. Regulatory framework/ reimbursement structure
    • 6.4.8.3. Competitive scenario
    • 6.4.8.4. Denmark market estimates and forecasts 2018 to 2030 (USD Million)
• 6.5. Asia Pacific
  • 6.5.1. Japan
    • 6.5.1.1. Key country dynamics
    • 6.5.1.2. Regulatory framework/ reimbursement structure
    • 6.5.1.3. Competitive scenario
    • 6.5.1.4. Japan market estimates and forecasts 2018 to 2030 (USD Million)
  • 6.5.2. China
    • 6.5.2.1. Key country dynamics
    • 6.5.2.2. Regulatory framework/ reimbursement structure
    • 6.5.2.3. Competitive scenario
    • 6.5.2.4. China market estimates and forecasts 2018 to 2030 (USD Million)
  • 6.5.3. India
    • 6.5.3.1. Key country dynamics
    • 6.5.3.2. Regulatory framework/ reimbursement structure
    • 6.5.3.3. Competitive scenario
    • 6.5.3.4. India market estimates and forecasts 2018 to 2030 (USD Million)
  • 6.5.4. Australia
    • 6.5.4.1. Key country dynamics
    • 6.5.4.2. Regulatory framework/ reimbursement structure
    • 6.5.4.3. Competitive scenario
    • 6.5.4.4. Australia market estimates and forecasts 2018 to 2030 (USD Million)
  • 6.5.5. South Korea
    • 6.5.5.1. Key country dynamics
    • 6.5.5.2. Regulatory framework/ reimbursement structure
    • 6.5.5.3. Competitive scenario
    • 6.5.5.4. South Korea market estimates and forecasts 2018 to 2030 (USD Million)
  • 6.5.6. Thailand
    • 6.5.6.1. Key country dynamics
    • 6.5.6.2. Regulatory framework/ reimbursement structure
    • 6.5.6.3. Competitive scenario
    • 6.5.6.4. Thailand market estimates and forecasts 2018 to 2030 (USD Million)
• 6.6. Latin America
  • 6.6.1. Brazil
    • 6.6.1.1. Key country dynamics
    • 6.6.1.2. Regulatory framework/ reimbursement structure
    • 6.6.1.3. Competitive scenario
    • 6.6.1.4. Brazil market estimates and forecasts 2018 to 2030 (USD Million)
  • 6.6.2. Argentina
    • 6.6.2.1. Key country dynamics
    • 6.6.2.2. Regulatory framework/ reimbursement structure
    • 6.6.2.3. Competitive scenario
    • 6.6.2.4. Argentina market estimates and forecasts 2018 to 2030 (USD Million)
• 6.7. MEA
  • 6.7.1. South Africa
    • 6.7.1.1. Key country dynamics
    • 6.7.1.2. Regulatory framework/ reimbursement structure
    • 6.7.1.3. Competitive scenario
    • 6.7.1.4. South Africa market estimates and forecasts 2018 to 2030 (USD Million)
  • 6.7.2. Saudi Arabia
    • 6.7.2.1. Key country dynamics
    • 6.7.2.2. Regulatory framework/ reimbursement structure
    • 6.7.2.3. Competitive scenario
    • 6.7.2.4. Saudi Arabia market estimates and forecasts 2018 to 2030 (USD Million)
  • 6.7.3. UAE
    • 6.7.3.1. Key country dynamics
    • 6.7.3.2. Regulatory framework/ reimbursement structure
    • 6.7.3.3. Competitive scenario
    • 6.7.3.4. UAE market estimates and forecasts 2018 to 2030 (USD Million)
  • 6.7.4. Kuwait
    • 6.7.4.1. Key country dynamics
    • 6.7.4.2. Regulatory framework/ reimbursement structure
    • 6.7.4.3. Competitive scenario
    • 6.7.4.4. Kuwait market estimates and forecasts 2018 to 2030 (USD Million)

Chapter 7. Competitive Landscape

• 7.1. Company Categorization
• 7.2. Recent Developments & Impact Analysis by Key Market Participants
• 7.3. Company Market Share Analysis, 2024
• 7.4. Company overview
  • 7.4.1. Laboratory Corporation of America Holding
    • 7.4.1.1. Company Overview
    • 7.4.1.2. Financial performance
    • 7.4.1.3. Product benchmarking
    • 7.4.1.4. Strategic initiatives
  • 7.4.2. Quest Diagnostics Incorporated
    • 7.4.2.1. Company Overview
    • 7.4.2.2. Financial performance
    • 7.4.2.3. Product benchmarking
    • 7.4.2.4. Strategic initiatives
  • 7.4.3. Agilent Technologies, Inc
    • 7.4.3.1. Company Overview
    • 7.4.3.2. Financial performance
    • 7.4.3.3. Product benchmarking
    • 7.4.3.4. Strategic initiatives
  • 7.4.4. Genome Medical, Inc
    • 7.4.4.1. Company Overview
    • 7.4.4.2. Financial performance
    • 7.4.4.3. Product benchmarking
    • 7.4.4.4. Strategic initiatives
  • 7.4.5. Thermo Fisher Scientific, Inc
    • 7.4.5.1. Company Overview
    • 7.4.5.2. Financial performance
    • 7.4.5.3. Product benchmarking
    • 7.4.5.4. Strategic initiatives
  • 7.4.6. Coriell Life Sciences
    • 7.4.6.1. Company Overview
    • 7.4.6.2. Financial performance
    • 7.4.6.3. Product benchmarking
    • 7.4.6.4. Strategic initiatives
  • 7.4.7. NeoGenomics Laboratories
    • 7.4.7.1. Company Overview
    • 7.4.7.2. Financial performance
    • 7.4.7.3. Product benchmarking
    • 7.4.7.4. Strategic initiatives
  • 7.4.8. FOUNDATION MEDICINE, INC
    • 7.4.8.1. Company Overview
    • 7.4.8.2. Financial performance
    • 7.4.8.3. Product benchmarking
    • 7.4.8.4. Strategic initiatives
  • 7.4.9. Illumina, Inc
    • 7.4.9.1. Company Overview
    • 7.4.9.2. Financial performance
    • 7.4.9.3. Product benchmarking
    • 7.4.9.4. Strategic initiatives
  • 7.4.10. Guardant Health
    • 7.4.10.1. Company Overview
    • 7.4.10.2. Financial performance
    • 7.4.10.3. Product benchmarking
    • 7.4.10.4. Strategic initiatives

관련자료